Scan Of The Brain Of A Patient Affected By Alzheimer's Disease Axial Section. The Food and Drug Administration approved aducanamab, the first drug to affect the underlying disease processes associated with Alzheimer's in June. BSIP/Universal Images Group via Getty hide caption
Among the topics discussed at the 2021 Alzheimer's Association International Conference were how doctors should think about prescribing the new drug Aduhelm and how COVID may affect the brain long-term. The Alzheimer's Association hide caption
As part of a clinical study, a patient with Alzheimer's disease receives an infusion of aducanumab at a Providence, R.I., hospital in 2019. Aducanumab is being marketed as Aduhelm. Charles Krupa/AP hide caption
Portrait of Phillip Lyn taken by his spouse, Kurt Rehwinkel, outside their home in St. Louis. Kurt Rehwinkel hide caption
Dr. William Burke reviews a PET brain scan at Banner Alzheimer's Institute in Phoenix in 2018. An experimental Alzheimer's drug from Biogen and Eisai is on the verge of a Food and Drug Administration decision. Matt York/AP hide caption